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Rationale: The 6-minute-walk test (6MWT) is a practical and
clinically meaningful measure of exercise tolerance with favor-
able performance characteristics in various cardiac and pulmo-
nary diseases. Performance characteristics in patients with
idiopathic pulmonary fibrosis (IPF) have not been systematically
evaluated.
Objectives: To assess the reliability, validity, and responsiveness
of the 6MWT and estimate the minimal clinically important
difference (MCID) in patients with IPF.
Methods: The study population included all subjects completing
a 6MWT in a clinical trial evaluating interferon gamma-1b (n 5
822). Six-minute walk distance (6MWD) and other parameters
were measured at baseline and at 24-week intervals using a stan-
dardized protocol. Parametric and distribution-independent cor-
relation coefficients were used to assess the strength of the
relationships between 6MWD and measures of pulmonary func-
tion, dyspnea, and health-related quality of life. Both distribu-
tion-based and anchor-based methods were used to estimate
the MCID.
Measurements and Main Results: Comparison of two proximal
measures of 6MWD (mean interval, 24 d) demonstrated good
reliability (coefficient 5 0.83; P , 0.001). 6MWD was weakly
correlated with measures of physiologic function and health-
related quality of life; however, values were consistently and
significantly lower for patients with the poorest functional status,
suggesting good construct validity. Importantly, change in
6MWD was highly predictive of mortality; a 24-week decline of
greater than 50mwas associatedwith a fourfold increase in risk of
death at 1 year (hazard ratio, 4.27; 95%confidence interval, 2.57–
7.10; P , 0.001). The estimated MCID was 24–45 m.
Conclusions: The 6MWT is a reliable, valid, and responsive mea-
sure of disease status and a valid endpoint for clinical trials in IPF.
Keywords: interstitial lung disease; idiopathic pulmonary fibrosis;
exercise test
Idiopathic pulmonary fibrosis (IPF) is a progressive, life-
threatening, interstitial lung disease of unknown etiology. It is
characterized by a progressive decline in lung function that
limits and eventually precludes routine physical activity. IPF is
the most common and the most lethal idiopathic interstitial
pneumonia, with a median survival of only 2–5 years after
diagnosis (1–3).
The 6-minute-walk test (6MWT) is a practical and reliable
measure of exercise tolerance that is widely used to assess the
functional status of patients with a variety of cardiac and pul-
monary diseases, including heart failure, pulmonary hyperten-
sion, and chronic obstructive pulmonary disease (COPD) (4–9).
However, studies evaluating the measurement properties of the
6MWT in patients with IPF have been limited by small sample
sizes or narrowly defined patient subsets and, presumably be-
cause of these limitations, have generally yielded inconsistent
results (10–18). Moreover, the minimal clinically important diff-
erence (MCID) for the 6MWT in patients with IPF has been
estimated in only two studies, each with limitations as noted
previously (16, 18). The MCID is the smallest difference in
a measure that may be perceived to be important, either bene-
ficial or harmful, and that would lead a clinician to consider
a change in a patient’s therapy (19). MCID is a clinically impor-
tant concept, because it may assist with the interpretation of
observed changes in a measure and may influence the perceived
success of an intervention. In addition, the MCID may have
implications for the design of clinical trials in terms of the
selection of primary and secondary endpoints and the determi-
nation of sample size (20, 21).
In the present study, we used data from the largest clinical
trial to date in patients with IPF to assess the reliability, validity,
and responsiveness of the 6MWT and estimate the MCID in
patients with this disease. This work has been presented in part
at the 2010 international meeting of the American Thoracic
Society (22).
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
The 6-minute-walk test is a widely used measure of
exercise tolerance that has been validated in a variety of
cardiac and pulmonary diseases. Performance characteris-
tics of the 6-minute-walk test have not been systematically
evaluated in patients with idiopathic pulmonary fibrosis.
What This Study Adds to the Field
Our findings suggest that the 6-minute-walk test is a reli-
able, valid, and responsive measure of exercise tolerance in
patients with idiopathic pulmonary fibrosis and that the
minimal clinically important difference in 6-minute-walk
distance is between 24 and 45 meters.
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METHODS
Study Population
The study population consisted of all randomized subjects in a placebo-
controlled Phase 3 clinical trial of interferon gamma-1b who completed
the 6MWT at the baseline study visit (n5 822). Analysis of outcomes in
the original study revealed no evidence of a treatment effect; therefore,
the present analysis included data from both treatment arms to
maximize study power (23). Criteria for enrollment in the original trial
have been described elsewhere (23). Briefly, eligible patients had
a confident IPF diagnosis according to the criteria of the American
Thoracic Society (24, 25), FVC greater than or equal to 55% of
predicted, diffusing capacity of carbon monoxide (DLCO) greater than
or equal to 35% of predicted, either FVC or DLCO less than or equal to
90% of predicted, and a 6MWT distance greater than or equal to 150 m.
Study Protocol
The 6MWT was performed at the screening and baseline visit and at
24-week intervals thereafter using a standardized protocol (see online
supplement). The test was performed indoors on a flat, straight corridor
with a hard surface. An oxygen titration procedure was performed at the
screening visit to establish a baseline flow rate for patients who required
supplemental oxygen. Before each 6MWT, patients were required to
have resting oxygen saturation as measured by pulse oximetry of at least
83% after 10 minutes of rest breathing room air or at the baseline O2
flow rate. Patients were instructed to walk as far as they could without
jogging or running; if they needed to slow down or stop to rest they were
permitted to do so and encouraged to resume walking as soon as they
were able. The test was stopped if the patient experienced chest pain,
intolerable dyspnea, leg cramps, diaphoresis, or desaturation below 83%.
Assessmentsofphysiologic function(FVC,DLCO,restingA-agradient),
dyspnea (University of California San Diego Shortness of Breath Ques-
tionnaire), and health-related quality of life (HRQL; St. George’s Re-
spiratory Questionnaire) were also performed at the screening or baseline
visit and at 24-week intervals thereafter (23). The total score of the
University of California San Diego Shortness of Breath Questionnaire
ranges from0–120, and the score increaseswith extent of dyspnea (26). The
St. George’s respiratory questionnaire is comprised of three respiratory-
specific domains: (1) symptoms, (2) activity, and (3) impacts. Each domain
of the questionnaire ranges from 0–100, with an increasing score indicating
worsening HRQL (27).
Statistical Analyses
Reliability was assessed based on the stability of 6MWTdistance (6MWD)
between the screening and baseline visits. The intraclass correlation
coefficient was used to assess the strength of the relationship; a value
greater than or equal to 0.80 was assumed to represent ‘‘good’’ reliability.
Analyses were conducted using observed data for the subgroup of patients
who did not receive supplemental oxygen during the 6MWT; for purposes
of comparison, analyses were also conducted using data for all randomized
patients.
Criterion validity was assessed based on relationships between 6MWD
and measures of physiologic status, dyspnea, and HRQL; distribution-
independent (Spearman) correlation coefficients were used to assess the
strength of these relationships. Strength of correlation was designated as
follows: greater than 0.5, large; 0.5–0.3, moderate; 0.3–0.1, small; and less
than 0.1, trivial (28). Construct validity was assessed by comparing the
mean 6MWD across subgroups of patients presumed to have different
capacities for physical endurance, defined on the basis of physiologic
function, dyspnea, and HRQL. Patients were stratified into subgroups
based on quintiles of the corresponding distributions. One-way analysis of
variance was used for statistical comparisons.
Responsiveness was assessed using Spearman correlation coeffi-
cients between the 48-week change in 6MWD (i.e., between baseline
and the Week 48 study visit) and changes over the same period in
measures of physiologic function, dyspnea, and HRQL. The relation-
ship between mean changes in 6MWD and changes in other measures
(stratified into quintiles) was examined using analysis of variance.
Responsiveness was also evaluated by examining the relationship
between 24-week change in 6MWD and 1-year risk of death using
a Cox proportional hazards model. Change in 6MWD was evaluated
over the 24-week periods immediately preceding the Week 24 and
Week 72 trial visits, respectively, and was defined initially based on
quintiles of the distribution and subsequently modified based on
clinical and statistical considerations. All deaths occurring over the
48-week period after the Week 24 and Week 72 visits, respectively,
were included in the analysis.
Both distribution-based and anchor-based methods were used to
estimate the MCID. Distribution-based methods included the standard
error of measurement (SEM) and effect size. SEM was calculated for
6MWD by multiplying the estimated standard deviation at baseline by
the square root of one minus the estimated reliability coefficient. One
SEM was defined to be the MCID; because the SEM is sample-
independent, MCID estimates based on the SEM are considered to be
bidirectional in nature (29, 30).
Effect size was calculated by dividing the difference in 6MWD
values at baseline and Week 48 by the estimated standard deviation at
baseline. A change in value corresponding to a ‘‘small’’ effect size was
considered to approximate the MCID (21, 31, 32). One-third of the
estimated standard deviation has also been suggested as an approxi-
mation of MCID (33).
The anchor-based method of estimating the MCID used the
criterion-referencing approach, which involved estimation of differ-
ences in 6MWD at baseline between patients who did and did not
experience selected health events during the subsequent 48-week
period. An independent samples t test was used for statistical compar-
isons.
RESULTS
Patient Characteristics
A total of 826 patients were randomized to interferon gamma-1b
(n5 551) or placebo (n5 275) in the Phase III trial; among these,
two patients in each group were missing baseline data for the
6MWT and were excluded from the study population (n 5 822)
(Table 1). Mean (6 SD) age at study entry was 66 (6 8) years
and 71% of study subjects were male. The mean (6 SD) value
for 6MWD at baseline was 392 (6 109) m; the interquartile
TABLE 1. BASELINE CHARACTERISTICS
Characteristic Value*
Age, yr
Mean (SD) 66 (7.8)
Median (IQR) 67 (61–72)
Sex, n (%)
Male 582 (70.8)
Female 240 (29.2)
6MWT Distance, m
Mean (SD) 392.4 (108.5)
Median (IQR) 395 (328–462)
FVC, % predicted
Mean (SD) 72.5 (12.7)
Median (IQR) 70.5 (62.2–80.7)
DLco, % predicted
Mean (SD) 47.4 (9.2)
Median (IQR) 46.1 (40.5–52.7)
Resting AaPo2, mm Hg
Mean (SD) 19.1 (10.7)
Median (IQR) 18.8 (11.9–25.9)
UCSD SOBQ score
Mean (SD) 34.9 (22.8)
Median (IQR) 30.4 (17–51)
SGRQ score
Mean (SD) 41.8 (18)
Median (IQR) 40.8 (28.6–54.3)
Definition of abbreviations: 6MWT 5 6-minute-walk test; AaPo2 5 alveolar-
arterial oxygen gradient; DLco 5 carbon monoxide diffusion capacity; IQR 5
interquartile range; SGRQ 5 St. George’s Respiratory Questionnaire; UCSD
SOBQ 5 University of California San Diego Shortness of Breath Questionnaire.
* n 5 822 except for DLco (820), AaPo2 (807), UCSD SOBQ (788), and SGRQ
(742).
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range was 328–462 m. There was substantial variation across
study subjects in physiologic measures, dyspnea, and HRQL.
Baseline characteristics of patients randomized to placebo versus
interferon gamma-1b, and the 722 patients who did not require
supplemental oxygen to complete the 6MWT, were similar (see
online supplement).
Reliability
The 6MWT seemed to have good reliability in patients with
IPF. The intraclass correlation coefficient for 6MWD between
the screening and baseline visits (mean interval, 24 d) was 0.83
(P , 0.001) using data for subjects who did not receive
supplemental oxygen (n 5 718), and 0.82 (P , 0.001) using
data for all randomized subjects (n 5 821). The correlation
coefficient was slightly lower (0.72; P , 0.001) for the small
subset of patients who required supplemental oxygen (n 5 103);
however, the degree to which this reflects test reliability in this
subgroup is uncertain, because these patients may have been
more likely to experience real change during the interval bet-
ween measurements. Because reliability is based on the pre-
sumption of stable disease between proximal measurements,
these patients are not optimal candidates for tests of reliability.
Validity
Correlations between 6MWD and measures of physiologic
function, dyspnea, and HRQL were in the expected direction,
but generally weak (absolute values of all coefficients, ,0.30;
P , 0.001) (Table 2). Patients in the fifth quintile (i.e., those
with the best scores) of physiologic function, dyspnea, and HRQL
generally had significantly better 6MWT values than those in
the other quintiles (i.e., those with poorer scores for physiologic
function, dyspnea, and HRQL) (Table 3).
Responsiveness
Correlations between changes in 6MWD and changes in measures
of physiologic function, dyspnea, and HRQL were in the expected
direction, but generally weak (absolute values of all coefficients,<
0.27; P , 0.001) (Table 4). Decline in 6MWD was generally
significantly greater for patients in the first and second quintiles of
change in physiologic function, dyspnea, and HRQL versus those
in the fifth quintile (Table 5). Both baseline 6MWD and the 24-
week change in 6MWD were highly predictive of death over the
subsequent 1-year period (Table 6). Importantly, the risk of death
was more than fourfold higher (hazard ratio [HR], 4.27; 95%
confidence interval [CI], 2.57– 7.10; P , 0.001) for patients with
a decline in 6MWD greater than 50 m, and more than threefold
higher (HR, 3.59; 95% CI, 1.95–6.63; P , 0.001) for those with
a decline of 26–50 m, compared with subjects for whom the decline
in 6MWD was less than or equal to 25 m. Treatment assignment
and the interaction term for treatment assignment and change in
6MWD were not important predictors of death, and the pro-
portional hazards assumption for change in 6MWD was satisfied.
To confirm the validity of including patients from both the
experimental and control arms in the analyses, data were
analyzed separately for the subgroups of patients who were
randomized to treatment with interferon gamma-1b and pla-
cebo, respectively, in the original clinical trial. There were no
meaningful differences between groups in 6MWD reliability,
validity, or responsiveness. Additionally, responsiveness was
similar when change in 6MWD was assessed over either 24 or 48
weeks.
Minimal Clinically Important Difference
The estimated SEM for the 6MWT, and the corresponding
MCID, was 45 m (95% CI, 42–47) (Table 7). The estimated
effect size for 6MWD was 0.28, based on a mean change in
value of 31 m between the baseline and Week 48 visits;
according to Cohen’s criteria (28), such an effect should be
considered ‘‘small.’’ One-third of the estimated standard de-
viation at baseline yielded a figure of 36.
Baseline 6MWT values were significantly different for
patients who experienced the composite endpoint of hospital-
ization or death versus those who did not; the corresponding
estimated MCID was 24 m (P 5 0.009). Differences in 6MWD
between patients who were hospitalized and those who were
not, and patients who died and those who did not, were 18 m
(P 5 0.086) and 27 m (P 5 0.059), respectively.
DISCUSSION
The 6MWT is a widely used measure of exercise tolerance in
patients with various cardiac and pulmonary diseases. From
a clinical perspective, it has the advantages of practicality and
safety; it requires no special equipment or advanced training,
and unlike maximal cardiopulmonary exercise testing, it can be
performed by all but the most severely impaired patients (34).
Moreover, because the 6MWT is self-paced, it is better toler-
ated and more reflective of daily activities than other maximal
exercise tests (10).
Based on these characteristics, the 6MWT represents a clin-
ically meaningful tool that may be particularly well-suited to the
assessment of functional status in patients with IPF. To date,
however, studies evaluating the performance characteristics of
the 6MWT in patients with IPF have been limited by small
sample size and have generally yielded inconsistent results (12,
13, 15–17). In a study of 29 patients with fibrotic idiopathic
interstitial pneumonia, Eaton and coworkers (13) reported
excellent intrasubject reproducibility for the 6MWT (coefficient
of variation 5 4.2%) and high correlations between 6MWD and
VO2max on maximal exercise testing (r2 5 0.78) and percent
predicted DLCO (r2 5 0.61). However, there was virtually no
correlation between 6MWD and percent predicted FVC (r2 5
0.06). Additionally, analysis of outcomes during a median
follow-up of 28 months revealed no significant relationship
between 6MWD and mortality. In a subsequent retrospective
analysis of 44 patients with IPF, Caminati and coworkers (17)
reported moderate correlations between 6MWD and both
percent predicted FVC and percent predicted DLCO (r 5 0.40
and 0.42, respectively). In contrast to the findings of Eaton and
coworkers (13), both 6MWD and change in 6MWD at 1 year
were predictors of mortality, although the magnitude of the HR
was small (HR 5 0.995 and HR 5 0.994 for 6MWD and change
in 6MWD, respectively).
TABLE 2. CORRELATION BETWEEN 6MWT DISTANCE AND
OTHER MEASURES
Variable N Coefficient* P Value†
FVC, % predicted 822 0.121 ,0.001
DLco, % predicted 820 0.135 ,0.001
Resting AaPo2,, mm Hg 807 20.188 ,0.001
UCSD SOBQ score 788 20.290 ,0.001
SGRQ score 742 20.255 ,0.001
Definition of abbreviations: 6MWT 5 6-minute-walk test; AaPo2 5 alveolar-
arterial oxygen gradient; DLco5 carbon monoxide diffusion capacity; SGRQ5 St.
George’s Respiratory Questionnaire; UCSD SOBQ 5 University of California San
Diego Shortness of Breath Questionnaire.
* Spearman correlation coefficient.
† One-way analysis of variance.
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In the present study, we assessed the reliability, validity, and
responsiveness of the 6MWT and estimated theMCID in a large,
well-defined cohort of patients with IPF who performed the test
according to a standardized protocol. Consistent with previous
studies, the distance walked during the 6MWT was highly re-
producible, demonstrating good reliability. Concurrent validity,
based on correlations with various measures of pulmonary func-
tion, was found to beweak; however, construct validity was found
to be much better, as 6MWT values were lowest for patients
with the poorest levels of physiologic function and the worst
scores for dyspnea and HRQL. Responsiveness, as assessed by
the relationship between 24-week changes in 6MWDand the risk
of 1-year mortality, was also found to be good. Patients experi-
encing a decline as small as 26m over 24weekwere found to be at
significantly higher risk of death than those in the referent group,
whereas those experiencing a decline of greater than 50mover 24
weeks had a fourfold increase in the risk of death at 1 year. This
finding is especially important, as it suggests that the 6MWT is an
important measure of prognosis, and thus might be used as a key
physiologic outcome parameter in clinical trials in patients with
IPF. Indeed, the sensitivity of the progression-free survival
endpoint, currently defined in most clinical trials in IPF on the
basis of a 10% decline in percent predicted FVC, might be
enhanced by the addition of a 6MWD criterion defined on the
basis a 50-m decrement. Such an endpoint has the potential to
increase the expected event rate and thereby decrease the
necessary size and duration of subsequent clinical trials.
A novel and important finding of our study was the observa-
tion that the 24-week change in 6MWDwas highly predictive of 1-
year mortality despite relatively weak correlations between
6MWD and various measures of pulmonary function known to
be independent predictors of mortality. This suggests that the
TABLE 3. MEAN (SD) 6MWT DISTANCE BY QUINTILES OF
OTHER MEASURES
Variable* N 6MWT Distance* P Value†
FVC, % predicted
,60.45 165 368.2 (103.7) 0.003
>60.45 to ,66.63 164 384.7 (114.1) 0.110
>66.63 to ,74.39 163 400 (106) 0.756
>74.39 to ,83.01 165 405.5 (108) 0.882
>83.01 165 403.7 (107.1) —
DLco,% predicted
,39.37 165 368.2 (104.5) ,0.001
>39.37 to ,43.93 162 379.8 (110.2) 0.014
>43.93 to ,48.57 164 398 (101) 0.341
>48.57 to ,54.45 165 405.9 (107.2) 0.771
>54.45 164 409.3 (115.1) —
Resting AaPo2,, mm Hg
>27.75 163 353.5 (109.1) ,0.001
>21.36 to ,27.75 160 386.1 (115.8) ,0.001
>15.97 to ,21.36 161 400.6 (101) 0.028
>10.12 to ,15.97 163 393.6 (102.2) 0.005
,10.12 160 426.8 (103.8) —
UCSD SOBQ score
>56.00 157 344.1 (109.2) ,0.001
>38.18 to ,56.00 156 383.9 (107.7) ,0.001
>25.00 to ,38.18 172 390.9 (105.6) ,0.001
>13.09 to ,25.00 143 400.9 (100.9) ,0.001
,13.09 160 443.3 (96.8) —
SGRQ score
>58.22 148 351.8 (106.1) ,0.001
>46.24 to ,58.22 148 369.6 (107.4) ,0.001
>36.03 to ,46.24 148 399.8 (111.6) ,0.001
>25.17 to ,36.03 149 398.7 (101.8) 0.005
,25.17 149 433.5 (98.8) —
Definition of abbreviations: 6MWT 5 6-minute-walk test; AaPo2 5 alveolar-
arterial oxygen gradient; DLco5 carbon monoxide diffusion capacity; SGRQ5 St.
George’s Respiratory Questionnaire; UCSD SOBQ 5 University of California San
Diego Shortness of Breath Questionnaire.
* Data are presented as mean (SD).
† One-way analysis of variance.
TABLE 4. CORRELATION BETWEEN CHANGE IN 6MWT
DISTANCE AND CHANGE IN OTHER MEASURES
Variable N Coefficient* P Value†
FVC, % predicted 697 0.270 ,0.001
DLco,% predicted 667 0.175 ,0.001
Resting AaPo2,, mm Hg 644 20.194 ,0.001
UCSD SOBQ score 628 20.203 ,0.001
SGRQ score 571 20.231 ,0.001
Definition of abbreviations: 6MWT 5 6-minute-walk test; AaPo2 5 alveolar-
arterial oxygen gradient; DLco 5 carbon monoxide diffusion capacity; IQR 5
interquartile range; SGRQ5 St. George’s Respiratory Questionnaire; UCSD SOBQ5
University of California San Diego Shortness of Breath Questionnaire.
* Spearman correlation coefficient.
† Analysis of variance.
TABLE 5. MEAN (SD) CHANGE IN 6MWT DISTANCE BY
QUINTILES OF CHANGE IN OTHER MEASURES
Variable* N 6MWT Distance, m* P Value†
FVC, % predicted
,29.96 132 298 (147.6) ,0.001
> 29.96 to ,24.58 139 248 (110.6) ,0.001
> 24.58 to ,21.30 144 26.2 (95.6) 0.437
> 21.30 to ,2.13 142 28.9 (108.5) 0.328
>2.13 140 4.3 (100.5) —
DLco,% predicted
,211.30 131 268.6 (141.1) ,0.001
> 211.30 to ,26.67 135 230.7 (122.2) 0.037
> 26.67 to ,22.92 132 217.6 (99.9) 0.253
> 22.92 to ,1.94 132 218.5 (102.6) 0.227
>1.94 137 21.6 (103.6) —
UCSD SOBQ score
>18.00 126 284.2 (162) ,0.001
>8.00 to ,18.00 133 228.9 (114) 0.345
>1.00 to ,8.00 132 213.2 (100.2) 0.915
> 28.00 to ,1.00 130 28.6 (84.8) 0.681
,28.00 107 214.8 (96.1) —
SGRQ score
>12.32 110 274.1(126.9) ,0.001
>5.53 to ,12.32 117 238.5 (132.1) 0.016
>0.35 to ,5.53 115 219.2 (118.4) 0.250
> 28.37 to ,0.35 113 223.2 (103.5) 0.160
,28.37 116 21.60 (98) —
Definition of abbreviations: 6MWT 5 6-minute-walk test; AaPo2 5 alveolar-
arterial oxygen gradient; DLco5 carbon monoxide diffusion capacity; SGRQ5 St.
George’s Respiratory Questionnaire; UCSD SOBQ 5 University of California San
Diego Shortness of Breath Questionnaire.
* Data are presented as mean (SD).
† One-way analysis of variance.
TABLE 6. COX PROPORTIONAL HAZARDS MODEL
Patient Visits (n) Deaths (n) HR (95% CI) P Value
D6MWT distance, m
,250 317 40 4.27 (2.57–7.10) ,0.001
250 to 226 117 18 3.59 (1.95–6.63) ,0.001
> 225 720 24
6MWT distance, m
,250 130 15 2.65 (1.48–4.74) 0.001
250 to 349 255 20 1.54 (0.91–2.60) 0.106
>350 823 47
Definition of abbreviations: D6MWT distance 5 24-week change in 6-minute
walk test distance; CI 5 confidence interval; HR 5 hazard ratio.
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6MWTmeasures a clinically important domain of the disease that
is not captured by these othermeasures. Although several studies
have identified change in percent predicted FVC as a strong
independent predictor of mortality in patients with IPF (3, 35–
37), no previous study assessing independent predictors of
mortality in patients with IPF has included change in 6MWD as
a covariate.Our data suggest that such informationmight provide
important incremental prognostic information. Future studies
using multivariate analysis are necessary to assess the contribu-
tion of changes in 6MWD to overall prognostic accuracy in
patients with IPF.
Consistent with the recommendations of Yost and Eton (33),
we used a number of alternative methods to estimate the MCID
for the 6MWT, including distribution-based and anchor-based
approaches. Based on these methods, our results suggest that the
MCID for the 6MWT is between 24 and 45m. This observation is
consistent with the findings of two previous studies in patients
with IPF (16, 18). In a study of 48 patients with diffuse parenchy-
mal lung disease, half of whom had IPF, Holland and coworkers
(16) reported a MCID ranging from 29 to 34 m. In a subsequent
analysis of 6MWD among 123 patients with IPF randomized to
the placebo arm of a clinical trial evaluating treatment with
bosentan, Swigris and coworkers (18) estimated that the mini-
mum important difference was 28 m (range, 10.8–58.5). Similar
values have been reported in patients with COPD. Based on
a single methodologic approach, Redelmeier and coworkers (38)
reported an estimated minimum important difference of 54 m. A
more recent analysis used data from nine trials among patients
with COPD and used a variety of methodologic approaches; the
MCID ranged from 29–42m, with the estimate based on the SEM
(35 m) favored by the authors (39). Thus, our finding that the
MCID for the 6MWT is between 24 and 45 m is consistent with
prior research focusing on the use of this instrument in patients
with COPD, IPF, and other diffuse parenchymal lung diseases.
Several study limitations should be noted. First, although our
analyses of responsiveness would have ideally been limited to
patients randomized to placebo in the clinical trial, we concluded
based on the absence of evidence for any treatment effect in the
clinical trial that the enhanced power of the study to characterize
the relationship between 6MWT and mortality justified the
inclusion of all randomized patients. Analyses of responsiveness
were robust when focusing on different populations (e.g., all
subjects, subjects not requiring supplemental oxygen, placebo
subjects) and when assessing changes over different periods of
time (e.g., 24wk vs. 48wk). Second, we did not have access to data
onpatients’ perception of their general well-being, and thus could
not use the patient-referencing approach, which is another
anchor-based method often used to assess MCID. Additionally,
in our criterion-referencing approach, we used hospitalization
and death as health events to estimate the MCID. These events
are not ‘‘minimally important’’ in nature; therefore, the resulting
MCID might overestimate the true smallest differences that
would be clinically important to patients with IPF. Estimates of
the MCID based on this approach may thus be viewed as
conservative, although they were largely consistent with esti-
mates yielded by the other approaches. Finally, patients with
severe physiologic impairment were excluded from enrollment in
the original clinical trial; therefore, the extent to which our
findings are generalizable to patients with severe functional
impairment is uncertain.
In conclusion, our results demonstrate that the 6MWT is
a reliable, valid, and responsive measure of exercise tolerance
in patients with IPF, and that a decline in 6MWD of 24–45 m
represents a small but clinically important difference. These
findingsdemonstrate that the 6MWTis a clinically usefulmeasure
of disease status and risk ofmortality, and represents an attractive
endpoint for clinical trials in patients with IPF. Future studies
using multivariable analysis are necessary to assess the contribu-
TABLE 7. ESTIMATION OF THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE IN 6MWT DISTANCE
IN PATIENTS WITH IPF
Standard Error of Measurement
Mean SD Correlation SEM (95% CI)
6MWT distance, m 392.4 108.3 0.83 45 (42-47)
Effect Size
Baseline Follow-up* Difference Effect Size
6MWT distance, m mean (SD) 397.9 (107.3) 367.4 (132.1) 230.5 (119) 0.28
Criterion Referencing†
N 6MWT Distance, m‡ P valuex
Hospitalization
Yes 669 397.1 (107.2) 0.086
No 128 379.3 (111.1)
Difference 17.9
Death
Yes 735 396.4 (107.3) 0.059
No 62 369.5 (112.4)
Difference 26.9
Hospitalization or death
Yes 621 399.6 (106) 0.009
No 176 375.4 (112.8)
Difference 24.2
Definition of abbreviations: 6MWT 5 6-minute-walk test; CI 5 confidence interval; IPF 5 idiopathic pulmonary fibrosis.
* Assessed at the Week 48 study visit.
† Comparison of baseline 6MWT distance between patients who did and did not experience selected health events during the
subsequent 48-week period.
‡ Data are presented as mean (SD).
x Independent samples t test.
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tion of changes in 6WMT distance to overall prognostic accuracy
in patients with IPF.
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